Cytokinetics CYTK Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's deferred revenue?
- Cytokinetics (CYTK) reported deferred revenue of $1.65M in Q1 2026.
- How has Cytokinetics's deferred revenue changed year-over-year?
- Cytokinetics's deferred revenue decreased by 96.8% year-over-year, from $52.37M to $1.65M.
- What is the long-term trend for Cytokinetics's deferred revenue?
- Over 5 years (2020 to 2025), Cytokinetics's deferred revenue has grown at a -55.0% compound annual growth rate (CAGR), from $87M to $1.61M.
- What does deferred revenue mean?
- Cash received in advance for work that has not yet been completed.
- How do you interpret deferred revenue?
- An increase often signals strong future demand or successful upfront billing, while a decrease may indicate revenue recognition or slowing sales.
- How does deferred revenue compare across companies?
- Common in biotech companies receiving upfront payments from licensing or collaboration agreements.